Clinical Hematology Research Development Program (K12) at Johns Hopkins

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): This proposal seeks to establish a Clinical Hematology Career Development Program in benign hematology at the Johns Hopkins Medical Institutions (JHMI). The next generation of clinical researchers in benign hematology will need to include individuals with the skills, attitudes, early research training and experience to capitalize on rapidly developing progress in benign hematology. In developing this program, we will use established research infrastructure, including free-standing Divisions of Hematology in Pediatrics and Internal Medicine that are dedicated to the care and study of benign hematologic disorders, as well as our Graduate Training Program in Clinical Investigation (GTPCI) at the Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health. Our specific aims are: a) To identify, train and develop creative and successful clinical investigators, with the capability to interact with, participate in, and lead multidisciplinary teams involved in clinical research, address complex problems and become national leaders in pediatric, adolescent and adult benign hematology;b) To provide trainees with the requisite skills, knowledge, attitude and experience for successful careers in clinical research in benign hematology. This training will include exposure to national and international leaders and curriculum in the multiple disciplines necessary for successful clinical research, including benign hematology, clinical trials design, epidemiology, statistics, research ethics and human subjects protection;c) To provide a rich mentoring environment. We will integrate multiple research resources and investigators available at the JHMI to provide optimal exposure of trainees to research experiences and training. We will focus our efforts in six areas where we feel there is particular strength within our institution: bone marrow failure and stem cell biology, sickle cell disease (SCD), myeloproliferative disorders, transfusion medicine, outcomes research and genetics. We will work with several established investigators and mentors to develop a structured curriculum in benign hematology and strong mentored research experiences for trainees. Careful and extensive mentoring will be the cornerstone of these efforts, with exposure to cutting edge research experiences. Through this program, we ultimately aim to provide a cadre of clinical researchers, who will become creative, independent investigators, care for patients and assume leadership roles in benign clinical hematology.